Administration of the nitric oxide synthase inhibitor NG-methyl- L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002)

Jan Bakker,Robert Grover,Angela McLuckie,Laurent Holzapfel,Jan Andersson,Robert F. Lodato,David Watson,Steven H. Grossman,Jill Donaldson,Jukka Takala

Administration of the nitric oxide synthase inhibitor NG-methyl- L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002)

2004

Jan Bakker
Robert Grover
Angela McLuckie
Laurent Holzapfel
Jan Andersson
Robert F. Lodato
David Watson
Steven H. Grossman
Jill Donaldson
Jukka Takala

ObjectiveTo assess the safety and efficacy of the nitric oxide synthase inhibitor 546C88 in patients with septic shock. The predefined primary efficacy objective was resolution of shock, defined as a mean arterial pressure ≥70 mm Hg in the absence of both conventional vasopressors and study drug, de

Keywords:

Nitric oxide synthase
Dobutamine
Septic shock
Intensive care medicine
Placebo
Sepsis
Anesthesia
Arginine
Mean arterial pressure
Nitric oxide
Medicine
intensive care

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

156

Citations